European Journal of Nuclear Medicine and Molecular Imaging最新文献

{"title":"Validation of SUV thresholds in [¹⁸F]SiTATE PET/CT for accurate meningioma segmentation.","authors":"Nabeel Mansour,Julian Joram,Freba Grawe,Anna Hinterberger,Johannes Rübenthaler,Konstantin Klambauer,Wolfgang G Kunz,Michael Winkelmann,Clemens C Cyran,Jens Ricke,Osman Öcal,Marcus Unterrainer,Klaus Jurkschat,Carmen Wängler,Björn Wängler,Ralf Schirrmacher,Alexander Nitschmann,Tobias Greve,Gabriel Sheikh,Adrien Holzgreve,Nathalie L Albert,Matthias P Fabritius","doi":"10.1007/s00259-025-07476-9","DOIUrl":"https://doi.org/10.1007/s00259-025-07476-9","url":null,"abstract":"PURPOSESomatostatin receptor (SSTR)-targeted PET/CT provides valuable clinical insights beyond standard imaging in meningioma patients. Due to its excellent diagnostic capabilities and favorable logistics, the 18F-labeled SSTR-targeting peptide SiTATE is increasingly in demand. We aimed to validate a recently proposed standard uptake value (SUV) threshold for accurate meningioma delineation in a clinically diverse patient cohort, including complex anatomical locations and lesions with prior surgical intervention.METHODSConsecutive patients with known or suspected meningioma who underwent [18F]SiTATE PET/CT and contrast enhanced cerebral MRI were included. Lesions were semi-automatically segmented on PET images using an individualized minimal SUV (SUVmin) within a manually defined volume of interest. Correlative CT and MRI images were used to refine segmentations for each lesion, identifying the optimal lesion-specific SUVmin to accurately capture the true volume of the meningioma. All lesions were additionally segmented using the recently proposed threshold of 4.0, and resulting volumes were compared.RESULTS61 patients with 109 lesions were analyzed: 40 (37%) extraosseous, 32 (29%) partial trans-osseous, and 37 (34%) predominantly intraosseous. The median optimal SUVmin for lesion delineation was 4.2. Osseous involvement did not significantly affect the median SUVmin (p = 0.1). Individualized SUV volumes showed excellent absolute agreement with those obtained using the fixed threshold of 4.0 (ICC[A,1] = 0.967; 95% CI: 0.952-0.977; p < 0.0001). However, 17 lesions (SUVmax < 4.2) were not captured by the fixed threshold.CONCLUSIONThe proposed SUV threshold of 4.0 showed promising results, supporting its suitability for clinical practice. Although limitations were evident, with 16% of lesions - primarily very small - showing reduced uptake and therefore not captured by this threshold, the study underscores its applicability in clinical practice.","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"52 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144684328","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Using 18F-FDG PET/CT-derived body composition features to predict lymphovascular invasion in non-small cell lung cancer.","authors":"Zewen Jiang,David Haberl,Clemens Spielvogel,Szabolcs Szakall,Peter Molnar,Josef Yu,Victor Lungu,Janos Fillinger,Ferenc Renyi-Vamos,Clemens Aigner,Balazs Dome,Christian Lang,Lukas Kenner,Zsolt Megyesfalvi,Marcus Hacker","doi":"10.1007/s00259-025-07435-4","DOIUrl":"https://doi.org/10.1007/s00259-025-07435-4","url":null,"abstract":"Lymphovascular invasion (LVI) in non-small cell lung cancer (NSCLC) is a critical prognostic marker linked to higher risks of metastasis and recurrence. This study aimed to develop a non-invasive predictive model using body composition features from 18F-FDG PET/CT imaging to assess LVI risk in early-stage NSCLC patients.METHODSWe retrospectively analyzed 248 patients, including 153 from Vienna (training cohort) and 95 from Budapest (validation cohort). Preoperative 18F-FDG PET/CT scans were used to assess tumor metabolic parameters, including standardized uptake values (SUVmax, SUVmean), metabolic tumor volume (MTV), and total lesion glycolysis (TLG), as well as body composition features, including visceral, subcutaneous, and intermuscular adipose tissue, skeletal muscle at L1-L5. LASSO regression identified key body composition features, and a logistic regression-based nomogram was constructed and validated through ROC analysis, calibration, decision curve analysis, and survival analysis.RESULTSLVI was present in 66/153 (43.1%) of Vienna and 39/95 (41.1%) of Budapest patients. The nomogram, developed using the Vienna training cohort, incorporating MTV, N stage, and body composition achieved an AUC of 0.839 and 0.790 in the Budapest validation cohort. Statistical tests confirmed that the nomogram significantly outperformed models based on either clinical (p = 7.92e-06) or imaging variables alone (p = 0.0474). Furthermore, LVI predicted by the nomogram was associated with significantly poorer 3-year recurrence-free and 5-year survival.CONCLUSIONIntegrating body composition with clinical and tumor metabolic features from PET/CT enables preoperative prediction of LVI in NSCLC, supporting improved risk stratification.","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"16 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144684358","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"From bench to bedside, blade, and back: FAP expression in juvenile angiofibroma. Potential implications for FAPI-PET/CT imaging and targeted therapy?","authors":"Lukas Pillong,Caroline Burgard,Florian Rosar,Betül Demirkol,Rafail Ebner,Maximilian Linxweiler,Alessandro Bozzato,Bernhard Schick,Silke Wemmert","doi":"10.1007/s00259-025-07468-9","DOIUrl":"https://doi.org/10.1007/s00259-025-07468-9","url":null,"abstract":"PURPOSEJuvenile angiofibroma (JA) is a rare, benign fibrovascular tumor that predominantly affects adolescent males. The underlying biological mechanisms remain poorly understood. Fibroblast activation protein (FAP), known for its involvement in tumor invasion, matrix remodeling, and angiogenesis, has been implicated in various malignancies but has not been studied in JA so far.METHODSWe investigated FAP expression in JA samples (N = 19) using real-time (RT)-PCR (N = 10) and immunohistochemistry (N = 18). In addition, Vimentin and PECAM1/CD31 were analyzed to further characterize the tumor microenvironment. For one patient, preoperative FAPI-PET/CT imaging was conducted, and FAP expression was correlated with radiotracer uptake. Postoperative histopathological analyses of the excised tumor were performed to validate the imaging findings.RESULTSWe found consistent expression of FAP, Vimentin and PECAM1/CD31 in all JA analyzed by RT-PCR. Moreover, substantial intra-and intertumor heterogeneity in FAP protein expression was observed, ranging from negative up to strong positive areas. Vimentin and PECAM1/CD31 showed variable expression patterns consistent with the fibrovascular character of JA. FAPI-PET/CT imaging accurately identified the tumor, with radiotracer uptake closely matching the distribution of FAP expression observed histologically.CONCLUSIONSThis study is the first demonstrating FAP expression in JA and validating its occurrence using FAPI-PET/CT imaging. The strong correlation between FAP expression and radiotracer uptake in FAPI-PET/CT highlights the potential of this imaging modality as a non-invasive diagnostic tool. This will improve diagnosis and is the basis for further investigations of FAP-targeted therapies for JA treatment.","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"143 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144684351","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dosimetry and kinetic modelling of [18F]JNJ-64511070, a novel PET ligand to quantify AMPA-associated TARP-γ8 receptors in the human brain.","authors":"Michel Koole,Mark E Schmidt,Anja Hijzen,Marie Cohilis,Corinne Vandermeulen,Kim Serdons,Sofie Celen,Guy Bormans,Michael Maher,Anna Katrin Szardenings,Wei Zhang,Hartmuth Kolb,Jan de Hoon,Koen Van Laere","doi":"10.1007/s00259-025-07428-3","DOIUrl":"https://doi.org/10.1007/s00259-025-07428-3","url":null,"abstract":"PURPOSEThe α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPA-R) are the primary determinants of synaptic strength in most glutamatergic neurons. Inhibition or negative modulation of AMPA-Rs is an attractive strategy for therapeutic intervention in central nervous system (CNS) disorders characterized by excessive neuronal activity. We report the clinical qualification of a AMPA-R associated TARP-γ8 specific PET ligand [18F]JNJ-64511070 in healthy volunteers including biodistribution, dosimetry and kinetic modelling.METHODSWhole body dosimetry was performed in 3 healthy male subjects (22-41y). Upon estimation of the normalized cumulated activity (NCA), the effective dose (ED) was calculated using OLINDA v1.1. In a second part, 120-minute dynamic brain scanning with arterial blood sampling was done in five healthy males (25-53y) to determine the appropriate kinetic model and evaluate time stability of total distribution volume (VT). Both 1- and 2-tissue compartment models (1-2TCM) as well as Logan graphical analysis (LGA) were considered to assess regional VT.RESULTSThe average ED (± SD) was 15.6 ± 1.0 µSv/MBq. Brain uptake of [18F]JNJ-64511070 was fast and showed slow clearance from brain. The intact parent tracer fraction was 80% after 80 min. 2TCM was the most appropriate kinetic model to estimate regional VT, with LGA showing very similar estimates. Regional VT values were similar across cortical brain regions (4.49 ± 0.66) with higher values for the hippocampus and amygdala (7.03 ± 1.64 and 5.76 ± 1.10 respectively) and lower values for cerebellum, striatum, thalamus and brain stem (2.82 ± 0.49, 2.84 ± 0.38, 1.12 ± 0.18 and 0.91 ± 0.16 respectively). Inter-subject VT variability was limited with a Coefficient of Variation (CoV) of 14.5% and 23.3% for cortical and medio-temporal regions respectively. The acquisition time could be reduced to 90 min, while further time reduction induced bias and increased variability in the medial temporal cortex.CONCLUSION[18F]JNJ-64511070 is the first 18F-labelled selective PET ligand for quantification of AMPA-R TARP-γ8 expression in human brain and can be used for testing target engagement of AMPA-R TARP-γ8 specific drug compounds, assisting in guiding dose selection and providing insight into the AMPA-R TARP-γ8 expression in healthy and diseased individuals.TRIAL REGISTRATIONClinicalTrials.gov database with clinical trial number NCT03270579, Registered 31 August 2017.","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"15 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144684359","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[177Lu] Lu-PSMA-617 treatment for metastatic castration-resistant prostate cancer (mCRPC) with cerebral and cerebellar metastases.","authors":"Gokce Belge Bilgin,Cem Bilgin,Brian J Burkett,Matthew P Thorpe,Ann T Packard,Fatma Fidanli,Daniel S Childs,Miguel Muniz,Jacob J Orme,J Fernando Quevedo,Sani H Kizilbash,Eugene D Kwon,Geoffrey B Johnson,Derek R Johnson,Oliver Sartor,Ayse Tuba Kendi","doi":"10.1007/s00259-025-07447-0","DOIUrl":"https://doi.org/10.1007/s00259-025-07447-0","url":null,"abstract":"BACKGROUNDCentral nervous system (CNS) metastases in prostate cancer are rare but pose a significant treatment challenge and are linked to poor prognosis. Data on the outcomes of this specific patient subgroup treated with radioligand therapy (RLT) remain scarce. In this study, we aim to leverage real-world clinical data to evaluate the outcomes of RLT with [177Lu] Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer (mCRPC) and CNS metastases.METHODSClinical and imaging data of patients who received their initial dose of [177Lu] Lu-PSMA-617 between March 2022 and April 2024 were retrospectively reviewed. All patients who were known to have at least one parenchymal CNS metastasis confirmed radiologically through dedicated neuroimaging, with or without histopathological confirmation, were included in the study. Central nervous system metastases (CNS) were defined as metastatic lesions involving the cerebrum, cerebellum, or spinal cord. The mCRPC patients with dural metastases but without parenchymal CNS disease were excluded.RESULTSA total of 589 patients underwent RLT with [177Lu] Lu-PSMA-617 for mCRPC, of whom 12 (2%, 12/589) had CNS metastases. Among these, eight patients (67%, 8/12) had pre-existing CNS lesions, while the remaining four patients (33%, 4/12) were diagnosed with CNS metastases after initiating RLT. Patients received no additional systemic or focal therapies concurrently with RLT. The mean follow-up period was 5.7 ± 6.9 months. The median overall survival from the initial dose of RLT was 4.5 months (range: 1.1-29.87 months). Among eight patients with pre-existing CNS metastases, CNS lesions resolved completely or nearly completely in three patients (37.5%, 3/8), while two patients (25%, 2/8) exhibited a mixed response, and three patients (37.5%, 3/8) experienced CNS disease progression following RLT. Among four patients diagnosed with CNS metastases after initiating therapy, three patients (75%, 3/4) experienced a rapid clinical decline necessitating urgent intervention, while the remaining patient (25%, 1/4) responded well to the therapy without developing new or worsening neurological symptoms. None of the patients were able to complete the full six cycles of RLT, with discontinuation mainly due to overall disease progression or infection-related complications.CONCLUSIONSOur study suggests that patients with CNS metastases, whether diagnosed before or after therapy, exhibited a poor prognosis, with a median survival of 4.5 months after initiation of RLT. Although a complete/near-complete radiologic response in the CNS lesions was observed in 25% of the patients, only two patients were able to complete more than three cycles of therapy. Given the small sample size, larger multicenter studies are needed to validate these findings.","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"8 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144669492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of two preprocessing methods for 18F-Flortaucipir PET quantification in Alzheimer's disease.","authors":"Elif Harput,Debora Elisa Peretti,Max Scheffler,Nicholas J Ashton,Kaj Blennow,Henrik Zetterberg,Ruben Smith,Giovanni B Frisoni,Valentina Garibotto,Cecilia Boccalini","doi":"10.1007/s00259-025-07452-3","DOIUrl":"https://doi.org/10.1007/s00259-025-07452-3","url":null,"abstract":"BACKGROUNDTau-Positron Emission Tomography (PET) has become central in Alzheimer's disease (AD) research and clinical settings. Multiple preprocessing pipelines for tau-PET quantification have been described, with satisfactory performance but direct comparisons remain scarse. Our study evaluates the comparability of two commonly used PET preprocessing methods, respectively in native and standard spaces, in quantifying tau deposition and in their ability to discriminate AD patients.METHODS209 subjects were included from the Geneva memory clinic including cognitively unimpaired (CU) individuals, mild cognitive impairment (MCI) and dementia patients. Images were processed in native and standard space using inferior cerebellar grey matter as reference region. Standardized uptake value ratios (SUVR) were extracted from AD-specific regions. Correlations between SUVR obtained by different methods and plasma biomarkers were assessed. ROC analyses compared the ability of the two methods to discriminate visually assessed tau status, amyloid-positive cognitively impaired from amyloid-negative CU, and subjects with declining cognition over time.RESULTSSUVR from the two methods were strongly correlated across all regions. However, SUVR values obtained with standard space method showed higher values. SUVR in the medial temporal lobe from native space processing provided a greater accuracy in discriminating positive scans and identifying subjects with cognitive decline. For all other analyses methods performed equally well. The correlation with plasma biomarkers was comparably high with both methods.CONCLUSIONWhile preprocessing in native and standard space is adequate for quantifying 18F-Flortaucipir PET and for discriminating AD patients, higher accuracy can be obtained in the mesial temporal regions and to predict cognitive decline using processing in native space.","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"24 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144664235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"18F-fluoroestradiol (18F-FES) PET/CT for guiding first-line treatment in patients with HR + /HER2- metastatic breast cancer: impact on progression free survival.","authors":"Yizhao Xie,Yifan Chen,Cheng Liu,Yannan Zhao,Chengcheng Gong,Shuyi Lin,Shaoli Song,Biyun Wang,Zhongyi Yang","doi":"10.1007/s00259-025-07459-w","DOIUrl":"https://doi.org/10.1007/s00259-025-07459-w","url":null,"abstract":"BACKGROUNDWhile CDK4/6 inhibitors combined with endocrine therapy (CDK4/6i+ET) have revolutionized treatment for HR+/HER2- metastatic breast cancer (MBC), inter-lesional estrogen receptor (ER) heterogeneity limits therapeutic efficacy in a subset of patients. Whole-body 18F-fluoroestradiol (18F-FES) PET/CT enables non-invasive ER quantification across all metastatic sites. However, whether 18F-FES-guided therapy selection improves clinical outcomes in relatively large sample cohorts is not yet well-established.PATIENTS AND METHODSWe screened all 1613 HR+/HER2- metastatic breast cancer (MBC) patients from 2020 to 2024 at Fudan University Shanghai Cancer Center. Patients who received standard first line treatment were enrolled in this retrospective study.RESULTSA total of 473 patients were included in the study. 156(33.0%) and 317 (67.0%) patients were screened or unscreened by 18F-FES-PET before first-line treatment. 111 patients with all-FES positive metastatic lesions and 17 patients with FES heterogeneity received CDK4/6 inhibitors combined with endocrine therapy. 21 patients with all-FES negative metastatic lesions and 7 patients with FES heterogeneity received chemotherapy (CT). As for the unscreened group, 236 received CDK4/6 inhibitors combined with endocrine therapy and 81 received CT. In CDK4/6 inhibitors combined with endocrine therapy cohort, FES-screened group showed a significantly prolonged progression-free survival (PFS) compared with unscreened group (mPFS 32.4 months versus 17.3 months, Hazard Ratio = 0.49; 95% CI, 0.34 to 0.69; p < 0.0001). And chemotherapy cohort showed superior PFS for screened patients as well (mPFS 11.38 months versus 8.91 months, Hazard Ratio = 0.56; 95% CI, 0.33 to 0.94; p = 0.026).CONCLUSIONSHR + /HER2- MBC patients with FES-guided initial treatment showed significantly better efficacy than those who had not been assessed by 18F-FES-PET/CT. This retrospective study highlights the crucial instructive role of FES assessment in evaluating ER expression in patients prior to administering first-line treatment. In the present study, improved PFS was observed when first-line therapy was guided by 18F-FES-PET in newly diagnosed HR+/HER2- MBC patients.","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"672 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144664171","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incidental myocardial uptake of 68Ga-FAPI-04 caused by hypertrophic cardiomyopathy in a patient with Immunoglobulin G4-related disease.","authors":"Silu Liu,Jie Feng,Hongzhe Zhang,Qingqing Pan,Yaping Luo","doi":"10.1007/s00259-025-07424-7","DOIUrl":"https://doi.org/10.1007/s00259-025-07424-7","url":null,"abstract":"","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"94 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144664172","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Does PARP1 up-regulation correlate with PSMA expression in patients with metastatic castration-resistant prostate cancer studied with [18F]PARPi and [68Ga]PSMA PET/CT?","authors":"Holger Einspieler,Heidemarie Ofner,Marius Ozenil,Clemens P Spielvogel,Ilva Kristiana Langrate,Melanie R Hassler,Lukas Nics,Karsten Bamminger,Pascal A T Baltzer,Shahrokh F Shariat,Marcus Hacker,Gero Kramer,Sazan Rasul","doi":"10.1007/s00259-025-07448-z","DOIUrl":"https://doi.org/10.1007/s00259-025-07448-z","url":null,"abstract":"PURPOSE[18F] Poly-ADP-ribose polymerase inhibitors (PARPi), a novel radiotracer, enables visualization of PARP1 upregulation by PET imaging. Here, we aimed to quantify PARPi uptake in tumor lesions of metastatic castration-resistant PCa (mCRPC) patients and perform a comparison with prostate specific membrane antigen (PSMA) expression using PET/CT scans.METHODSData from 22 male patients with mCRPC, who underwent [18F]PARPi and [68Ga]Ga-PSMA-11 PET/CT scans, were retrospectively quantified. Lesions with relevant PARPi uptake (higher than background) were delineated and correlated with their [68Ga]PSMA uptake using standardized uptake values (SUV). Additionally, a comparison was performed to investigate the effects of homologous recombination deficiency (HRD) alterations on PARPi tumor uptake.RESULTSThe majority of metastatic PCa lesions that exhibited PARPi uptake were located in the bones (n = 57), with mean SUVmax values of 4.9 ± 1.5 for PARPi and 30.9 ± 28.3 for [68Ga]PSMA. Additionally, 3 local prostate lesions, 14 lymph nodes and 4 further metastatic lesions were detected. Significant correlations were identified between PARPi- and [68Ga]PSMA uptake, as measured by SUVmean (r = 0.48, p < 0.001), SUVpeak (r = 0.48, p < 0.001) and SUVmax (r = 0.43, p < 0.001) of the osseous metastatic lesions and SUVpeak (r = 0.49, p = 0.04) of extraosseous lesions. No significant differences were found between PARPi uptake of metastatic lesions in patients with or without HRD alterations (all p > 0.05).CONCLUSIONResults showed a considerable uptake of [18F]PARPi in mCRPC patients and indicated a correlation between PARPi uptake and PSMA expression, suggesting the potential of using [18F]PARPi as a diagnostic imaging tool in mCRPC patients. More studies are needed to evaluate the clinical benefit of this innovative radiotracer.","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"267 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144664150","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"DTI-ALPS index-assessed glymphatic dysfunction mediates Alzheimer's cognitive decline via amyloid-β-dependent pathways: multimodal PET/MRI study.","authors":"Yan Zhang,Gan Huang,Jieli Geng,Xia Li,Mei Xin,Peizhe Yuan,Yue Wang,Qun Xu,Gang Wang,Gang Huang,Jianjun Liu,Chenpeng Zhang","doi":"10.1007/s00259-025-07445-2","DOIUrl":"https://doi.org/10.1007/s00259-025-07445-2","url":null,"abstract":"PURPOSEThe role of glymphatic dysfunction in Alzheimer's disease (AD), as measured by diffusion tensor imaging along perivascular spaces (DTI-ALPS) indexing of perivascular function, its progression, and its interaction with amyloid-β (Aβ) and tau proteins, remains controversial. To investigate whether the DTI-ALPS index mediates AD-related cognitive decline through Aβ/tau-dependent pathways using tri-tracer PET/MRI.METHODSThis retrospective study (2021-2024) analyzed 140 participants (median age 69.00 [61.00, 74.00] years; 84 women), including 99 with AD (37 early-onset [EOAD], 62 late-onset [LOAD]), 35 with mild cognitive impairment (MCI), and 6 with subjective cognitive decline (SCD). All participants underwent simultaneous [1⁸F] Florbetapir (Aβ), [1⁸F] PI-2620(tau), and [1⁸F] FDG PET/MRI with DTI-ALPS indexing for glymphatic function quantification. Causal mediation analysis was used to assess the relationships between biomarkers (P < 0.05).RESULTSThe ALPS index progressively decreased across clinical stages (SCD: 1.51 ± 0.08 vs. MCI: 1.37 ± 0.13 vs. AD: 1.32 ± 0.14; P = 0.001), correlating with higher Aβ-PET (r = - 0.31, P < 0.001), tau-PET (ρ = - 0.18, P = 0.035), and FDG-PET scores (ρ = - 0.22, P = 0.008). Aβ-PET fully mediated the ALPS effects on FDG-PET (β = - 0.14, P = 0.002) and cognition (β = 0.12 ~ 0.14, P < 0.01), independent of tau (P > 0.05). The Aβ-negative subgroups showed correlations with ALPS-age (r = - 0.48, P = 0.007), ALPS-education (r = 0.39, P = 0.035), and ALPS-cognition (MoCA: r = 0.62, P < 0.001). The Aβ-positive subgroups revealed inverse ALPS-Aβ associations (ρ = - 0.27, P = 0.010; age/education-adjusted ρ = - 0.24, P = 0.022) alongside positive adjusted correlations with cognition (MMSE: ρ = 0.28, P = 0.009). EOAD exhibited distinct ALPS-cognition relationships compared to LOAD (MMSE: r = - 0.39, P = 0.016 vs. ρ = - 0.06, P = 0.620).CONCLUSIONDTI-ALPS quantifies glymphatic dysfunction driving AD progression predominantly through Aβ-dependent pathways, with EOAD demonstrating distinct neuroimaging-cognition relationships compared to LOAD.","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"10 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144652734","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}